Biogen Sees Interest In Potential Biosimilars Deal
Biosimilars Turnover Steady In Q2; Also Provides Update On Tysabri And Tecfidera Rivals
As Biogen provided an update on a potential sale of its biosimilars business – with the firm “engaged with multiple interested parties” – it also revealed Q2 sales and offered insights into off-patent competition to its Tysabri and Tecfidera brands.
